Page last updated: 2024-11-05

trimetrexate and Urinary Bladder Neoplasms

trimetrexate has been researched along with Urinary Bladder Neoplasms in 3 studies

Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.

Research Excerpts

ExcerptRelevanceReference
"Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important."2.67An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. ( Elson, P; Khandakar, J; Trump, DL; Witte, RS, 1994)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roth, BJ1
Bajorin, DF1
Scher, HI1
Witte, RS1
Elson, P1
Khandakar, J1
Trump, DL1

Reviews

1 review available for trimetrexate and Urinary Bladder Neoplasms

ArticleYear
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
    The Journal of urology, 1995, Volume: 153, Issue:3 Pt 2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

1995

Trials

2 trials available for trimetrexate and Urinary Bladder Neoplasms

ArticleYear
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
    The Journal of urology, 1994, Volume: 152, Issue:5 Pt 1

    Topics: Carcinoma, Transitional Cell; Humans; Trimetrexate; Urinary Bladder Neoplasms

1994
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
    Cancer, 1994, Feb-01, Volume: 73, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Drug Administration Schedule; Female;

1994